Nov 12, 2024
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
Nov 07, 2024
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
Nov 01, 2024
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Oct 24, 2024
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
Oct 23, 2024
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
Aug 14, 2024
Cadrenal Therapeutics to Present at Upcoming Investor Conferences
Aug 07, 2024
Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
Aug 06, 2024
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
Jul 17, 2024
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
Jun 11, 2024
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
May 23, 2024
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 09, 2024
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update
Apr 09, 2024
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
Mar 11, 2024
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
Feb 26, 2024
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
Jan 04, 2024
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference